Inflammasome Therapeutics: Funding, Investors & Team (Sep 2026)
Inflammasome Therapeutics focuses on creating treatments for common, progressive illnesses such as Alzheimer's disease and Parkinson's disease.
Inflammasome Therapeutics has raised $16.0M across 2 funding rounds on record, the most recent an undisclosed round of $13.2M announced in May 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Inflammasome Therapeutics Company Profile and Key Stats
Latest funding round on record: May 2026.
Inflammasome Therapeutics Funding Rounds
Inflammasome Therapeutics raised $2.8M in an undisclosed round announced in Aug 2023.
2.8 years later, an undisclosed round of $13.2M was announced in May 2026.
Inflammasome Therapeutics Founders and Leadership Team
Contact details for the Inflammasome Therapeutics team: 1 of 2 have an email address on file, 1 has a LinkedIn profile.
Start 14-day free trial →Inflammasome Therapeutics Funding Compared to Other Biotechnology Startups
Inflammasome Therapeutics' latest round of $13.2M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Inflammasome Therapeutics in Biotechnology and Newton
Companies Similar to Inflammasome Therapeutics
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Inflammasome Therapeutics Funding FAQs
What does Inflammasome Therapeutics do?
Inflammasome Therapeutics focuses on creating treatments for common, progressive illnesses such as Alzheimer's disease and Parkinson's disease.
How much funding has Inflammasome Therapeutics raised?
Inflammasome Therapeutics has raised $16.0M across 2 rounds on record. The most recent is an undisclosed round of $13.2M announced in May 2026.
When did Inflammasome Therapeutics last raise funding?
Inflammasome Therapeutics' most recent funding round on record is an undisclosed round of $13.2M, announced in May 2026.
Who founded Inflammasome Therapeutics?
FundedIQ lists Jayakrishna Ambati (Founder), Paul Ashton (Founder) at Inflammasome Therapeutics.
Where is Inflammasome Therapeutics headquartered?
Inflammasome Therapeutics is based in Newton, Massachusetts, United States.
How many employees does Inflammasome Therapeutics have?
Inflammasome Therapeutics is in the 1-10 employee band.
How does Inflammasome Therapeutics' funding compare to other Biotechnology startups?
Inflammasome Therapeutics' latest round of $13.2M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Inflammasome Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inflammasome Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.